“…These results suggest continuing interest in the clinical study of this agent. In the meantime, several other compounds containing the 2,2-dimethylaziridine moiety were synthesized and found to be effective against a spectrum of transplanted tumors in rodents (21)(22)(23)(24)(25)(26). Two of these agents, ethyl bis(2,2-dimethyl-l-aziridinyl)phosphinate (11) (23,24) and tris(2,2-dimethyl-l-aziridinyl)phosphine oxide (111) (25), which showed particularly potent activities against leukemia L-1210 in mice, passed through the preclinical pharmacology stage (24) and are presently undergoing preliminary evaluation against solid tumors in man.…”